دورية أكاديمية
Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis.
| العنوان: | Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis. |
|---|---|
| المؤلفون: | Monreal E; Department of Neurology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Red Española de Esclerosis Múltiple, Red de Enfermedades Inflamatorias, Universidad de Alcalá, Madrid, Spain., Ruiz PD; Department of Pharmacy, Hospital Nuestra Señora de Candelaria, Tenerife, Spain., San Román IL; Servicio de Salud de Castilla-La Mancha (SESCAM), Albacete, Spain., Rodríguez-Antigüedad A; Department of Neurology, Hospital de Cruces, Bilbao, Spain., Moya-Molina MÁ; Hospital Universitario Puerta del Mar, Cádiz, Spain., Álvarez A; Roche Farma, Madrid, Spain., García-Arcelay E; Roche Farma, Madrid, Spain., Maurino J; Roche Farma, Madrid, Spain., Shepherd J; Omakase Consulting, Barcelona, Spain., Cabrera ÁP; Omakase Consulting, Barcelona, Spain., Villar LM; Department of Immunology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain. |
| المصدر: | Frontiers in public health [Front Public Health] 2024 Apr 22; Vol. 12, pp. 1397845. Date of Electronic Publication: 2024 Apr 22 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Editorial Office |
| مواضيع طبية MeSH: | Multiple Sclerosis*/blood , Multiple Sclerosis*/diagnosis , Multiple Sclerosis*/cerebrospinal fluid , Biomarkers*/blood , Biomarkers*/cerebrospinal fluid , Neurofilament Proteins*/blood , Neurofilament Proteins*/cerebrospinal fluid , Decision Support Techniques*, Humans ; Spain ; Adult ; Female ; Middle Aged ; Male |
| مستخلص: | Introduction: Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease that represents a leading cause of non-traumatic disability among young and middle-aged adults. MS is characterized by neurodegeneration caused by axonal injury. Current clinical and radiological markers often lack the sensitivity and specificity required to detect inflammatory activity and neurodegeneration, highlighting the need for better approaches. After neuronal injury, neurofilament light chains (NfL) are released into the cerebrospinal fluid, and eventually into blood. Thus, blood-based NfL could be used as a potential biomarker for inflammatory activity, neurodegeneration, and treatment response in MS. The objective of this study was to determine the value contribution of blood-based NfL as a biomarker in MS in Spain using the Multi-Criteria Decision Analysis (MCDA) methodology. Materials and Methods: A literature review was performed, and the results were synthesized in the evidence matrix following the criteria included in the MCDA framework. The study was conducted by a multidisciplinary group of six experts. Participants were trained in MCDA and scored the evidence matrix. Results were analyzed and discussed in a group meeting through reflective MCDA discussion methodology. Results: MS was considered a severe condition as it is associated with significant disability. There are unmet needs in MS as a disease, but also in terms of biomarkers since no blood biomarker is available in clinical practice to determine disease activity, prognostic assessment, and response to treatment. The results of the present study suggest that quantification of blood-based NfL may represent a safe option to determine inflammation, neurodegeneration, and response to treatments in clinical practice, as well as to complement data to improve the sensitivity of the diagnosis. Participants considered that blood-based NfL could result in a lower use of expensive tests such as magnetic resonance imaging scans and could provide cost-savings by avoiding ineffective treatments. Lower indirect costs could also be expected due to a lower impact of disability consequences. Overall, blood-based NfL measurement is supported by high-quality evidence. Conclusion: Based on MCDA methodology and the experience of a multidisciplinary group of six stakeholders, blood-based NfL measurement might represent a high-value-option for the management of MS in Spain. Competing Interests: EM reported receiving research grants, travel support, or honoraria for speaking engagements from Almirall, Merck, Roche, Sanofi, Bristol Myers Squibbb, Biogen, Janssen, and Novartis. PR reported receiving personal fees from Roche for the participation in the study. IR reported receiving personal fees from Roche for the participation in the study. AR-A reported receiving research grants, travel support, or honoraria for speaking engagements from Merck, Biogen, Roche, Genzyme, Teva, Mylan and Celgene. MM-M reported receiving personal fees from Roche for the participation in the study. AÁ, EG-A, and JM are employees of Roche Farma Spain. JS and ÁC are employees of Omakase Consulting S.L. Omakase Consulting S.L. received funding from Roche Farma Spain. LV reported receiving research grants and personal fees from Merck, Roche, Sanofi, Bristol Myers Squibb, Biogen, and Novartis. (Copyright © 2024 Monreal, Ruiz, San Román, Rodríguez-Antigüedad, Moya-Molina, Álvarez, García-Arcelay, Maurino, Shepherd, Cabrera and Villar.) |
| References: | Front Neurosci. 2021 Mar 25;15:654942. (PMID: 33841093) Int J Technol Assess Health Care. 2017 Jan;33(1):111-120. (PMID: 28434413) Lancet Neurol. 2022 Mar;21(3):246-257. (PMID: 35182510) Farm Hosp. 2022 Jul 04;46(4):208-214. (PMID: 36183218) Epilepsy Behav. 2022 Jul;132:108711. (PMID: 35588562) Neurol Neuroimmunol Neuroinflamm. 2019 Apr 08;6(3):e555. (PMID: 31119188) Curr Opin Neurol. 2016 Jun;29(3):254-62. (PMID: 27075495) Neurologia (Engl Ed). 2024 Mar;39(2):196-208. (PMID: 38237804) Curr Opin Cell Biol. 2015 Feb;32:121-30. (PMID: 25726916) Med Decis Making. 2012 Mar-Apr;32(2):376-88. (PMID: 21987539) Epilepsy Behav. 2023 Aug;145:109350. (PMID: 37480633) JAMA. 2021 Feb 23;325(8):765-779. (PMID: 33620411) BMC Health Serv Res. 2008 Dec 22;8:270. (PMID: 19102752) Mult Scler. 2020 Jan;26(1):17-19. (PMID: 31625807) Eur J Neurol. 2019 Jan;26(1):27-40. (PMID: 30300457) Ann Clin Transl Neurol. 2020 Jun;7(6):945-955. (PMID: 32452160) Rev Neurol. 2021 Aug 1;73(3):101-110. (PMID: 34291447) Mult Scler Relat Disord. 2023 Sep;77:104893. (PMID: 37481820) Mult Scler. 2012 Mar;18(3):372-6. (PMID: 21878452) J Neurol. 2023 Jul;270(7):3315-3328. (PMID: 37184659) Medicine (Baltimore). 2024 Feb 23;103(8):e37297. (PMID: 38394496) JAMA Neurol. 2023 Mar 1;80(3):287-297. (PMID: 36745446) EBioMedicine. 2024 Mar;101:104970. (PMID: 38354532) Value Health. 2016 Jan;19(1):1-13. (PMID: 26797229) JAMA Neurol. 2019 Nov 01;76(11):1359-1366. (PMID: 31403661) JAMA Neurol. 2023 Apr 1;80(4):397-403. (PMID: 36848127) Brain. 2023 Feb 13;146(2):421-437. (PMID: 36083979) Rev Neurol. 2019 Jul 1;69(1):32-38. (PMID: 31236909) Neurology. 2017 Feb 28;88(9):826-831. (PMID: 28148632) J Neurol. 2023 Apr;270(4):1908-1930. (PMID: 36520240) Int J Mol Sci. 2022 May 24;23(11):. (PMID: 35682558) Brain. 2021 Nov 29;144(10):2954-2963. (PMID: 34180982) Eur J Radiol. 2023 Sep;166:111019. (PMID: 37549559) J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881. (PMID: 30967444) Mult Scler Relat Disord. 2022 Feb;58:103398. (PMID: 35216781) Int J Technol Assess Health Care. 2018 Jan;34(5):519-526. (PMID: 30348241) Lancet Neurol. 2024 Apr;23(4):344-381. (PMID: 38493795) Value Health. 2016 Mar-Apr;19(2):125-37. (PMID: 27021745) J Neurol. 2024 Apr;271(4):1497-1514. (PMID: 37864717) Epilepsy Behav. 2021 Sep;122:108222. (PMID: 34371462) J Neurol. 2024 Apr;271(4):1599-1609. (PMID: 38085343) |
| فهرسة مساهمة: | Keywords: biomarker; inflammation; multi-criteria decision analysis (MCDA); multiple sclerosis (MS); neurodegeneration; neurofilaments; treatment response |
| المشرفين على المادة: | 0 (Biomarkers) 0 (Neurofilament Proteins) 0 (neurofilament protein L) |
| تواريخ الأحداث: | Date Created: 20240507 Date Completed: 20240507 Latest Revision: 20240529 |
| رمز التحديث: | 20240529 |
| مُعرف محوري في PubMed: | PMC11073490 |
| DOI: | 10.3389/fpubh.2024.1397845 |
| PMID: | 38711771 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2296-2565 |
|---|---|
| DOI: | 10.3389/fpubh.2024.1397845 |